Skip to main content

Illumina Extends Supply Agreement With Foundation Medicine, Collaborates with PerkinElmer

NEW YORK (GenomeWeb) – Foundation Medicine and Illumina have amended their supply and service agreement and extended the terms of the agreement through June 6, 2023, according to a document filed with the US Securities and Exchange Commission by Foundation Medicine on Thursday.

According to the agreement, Illumina will supply Foundation Medicine and its German subsidiary with sequencers, reagents, other consumables, as well as service contracts to maintain and repair its instruments. Foundation Medicine has committed to purchasing a certain amount of reagents and other consumables every six months. Sequencers and service contract prices will be based on Illumina's list prices, while reagents and consumables prices are fixed for a set period of time.

Separately, Illumina also said today that it has codeveloped a metagenomic sequencing workflow with PerkinElmer. The workflow combines Illumina's Nextera DNA Flex library prep kit with PerkinElmer's automation and will enable DNA to be extracted and sequenced from samples without needing to culture the bacteria.

The workflow is "aimed at significantly improving the discovery of microbiota-related disorders," Mitu Chaudhary, manager of product management and library preparation solutions at Illumina, said in a statement.

Mark Dupal, global portfolio director or microfluidics and automation, applied genomics at PerkinElmer, added that the automation would "enable greater laboratory efficiency, reduce labor costs, and generate consistent, high-quality data."